precision is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Method validation establishes that an HPLC procedure is suitable for its intended use. Key parameters include accuracy, precision, specificity, linearity, range, limit of detection, limit of quantitation, and robustness. Accuracy measures agreement with a true or accepted value, while precision describes repeatability and intermediate precision. Specificity confirms that the method measures the analyte without interference from impurities, degradants, or excipients. Validation is documented in a protocol and report, and acceptance criteria are set before experiments begin. Regulatory guidance varies by region, but the general principles are widely harmonized.
System suitability testing is performed before and during analytical runs to confirm that the instrument and method are working as expected. Common checks include retention time, peak area, resolution between critical pairs, tailing factor, and theoretical plate count. Results are compared with predefined limits, and a failed check requires investigation before sample results are reported. Quality control samples at low, middle, and high concentrations are injected at intervals to monitor accuracy and precision. Blank injections detect carryover and contamination, while control charts track performance over time.
Data handling and documentation are central to HPLC quality control. Electronic systems should have audit trails that record changes to methods, sequences, and results. Integration parameters, such as peak baseline and threshold, can affect reported areas and must be defined in advance. Out-of-specification results trigger a structured investigation that may include reanalysis, instrument checks, and review of sample preparation. Regulatory inspections often examine raw data, audit trails, and training records to verify that reported results are traceable and reliable.
Developing an HPLC method begins with defining the purpose, such as quantifying a main component, measuring impurities, or confirming identity. Analysts select separation mode, column, mobile phase, detection, and sample preparation based on analyte properties and matrix. Experiments vary solvent strength, pH, buffer type, and temperature to achieve resolution between critical peaks. The goal is a robust method that produces reliable results across instruments and operators. Method development often involves trial runs and statistical optimization.
Validation demonstrates that a method is suitable for its intended use. Typical performance characteristics include accuracy, precision, specificity, linearity, range, limit of detection, limit of quantitation, and robustness. Regulators and standards organizations provide frameworks, but specific requirements depend on the application and jurisdiction. System suitability tests are run before sample analysis to confirm resolution, peak symmetry, retention time repeatability, and sensitivity. A validated method is not permanently fixed; changes may require partial or full revalidation.
| Property | Value | Notes |
|---|---|---|
| Validation parameter | Accuracy | Measured value compared with true or accepted value |
| Precision type | Repeatability | Same analyst, instrument, and short time interval |
| Linearity range | 50–150% of target concentration | Common for assay methods; method-dependent |
| Limit of quantitation | Signal-to-noise ratio of 10:1 | Lowest concentration with acceptable precision |
| Common synonyms | Method validation, analytical validation | Documented confirmation that a method is suitable |
System suitability testing is performed before and during analytical runs to confirm that the instrument and method are working as expected. Typical checks include retention time, peak area precision, resolution between critical pairs, tailing factor, and theoretical plate count. Acceptance criteria are set in the method or pharmacopeial monograph. If a suitability check fails, the run may be rejected and the instrument or sample preparation may need investigation. This practice helps prevent release of data from a system that has drifted out of control.
Quality control samples are inserted at intervals to monitor accuracy and precision throughout a batch. Blank samples detect contamination, while spiked samples assess recovery from the sample matrix. Calibration standards establish the relationship between detector response and concentration, and control samples are prepared independently from them whenever possible. Laboratories also participate in proficiency testing and maintain audit trails, instrument logs, and reagent records. Ongoing review of control charts can reveal trends before they cause out-of-specification results.
Method validation establishes that an HPLC procedure is suitable for its intended purpose. Typical parameters include accuracy, precision, specificity, linearity, range, limit of detection, limit of quantitation, robustness, and solution stability. Accuracy reflects closeness to a reference value, while precision reflects agreement among repeated measurements. Specificity shows whether the method can measure the analyte without interference from matrix components. Validation is documented through protocols and reports, and the required extent depends on the method's use and regulatory context.
Routine quality control uses system suitability, blank injections, check standards, and control samples to detect drift or contamination. System suitability criteria may specify minimum resolution, maximum tailing factor, and a permitted range for repeated injections. Blank injections reveal carryover or solvent contamination, while check standards confirm calibration accuracy over a batch. Control samples with known analyte levels can show whether results remain within statistical limits. When a control result falls outside limits, the analyst investigates the cause and may invalidate affected results before repeating the batch.
Documentation and traceability are central to regulated HPLC testing. Records typically include instrument logs, column history, mobile-phase preparation, sample preparation, injection sequences, raw chromatograms, and audit trails. Electronic systems may require user access controls, time-stamped changes, and backup procedures. Training records show that analysts are qualified for assigned methods. Audits and inspections check whether written procedures match actual practice and whether deviations are documented. These controls support reproducibility and allow results to be reconstructed if questions arise later.
High-performance liquid chromatography is an analytical technique that separates components in a liquid sample. A pump moves a liquid mobile phase through a column packed with a solid stationary phase. Compounds interact differently with both phases and travel at different rates, leaving the column at distinct retention times. A detector records these arrivals as peaks on a chromatogram. The resulting pattern supports identification and quantification of substances in mixtures. Modern instruments use high pressure to force solvent through small particles, which improves speed and resolution compared with older low-pressure liquid chromatography methods.
Separation in HPLC depends on the chemistry of the stationary phase, the composition of the mobile phase, and the physical properties of the column. Reverse-phase separations use a nonpolar stationary phase and a polar mobile phase, and they are common for many organic compounds. Ion-exchange, size-exclusion, and normal-phase modes serve other classes of analytes. Gradient elution changes solvent strength over time, while isocratic elution holds it constant. Flow rate, temperature, particle size, and column length all influence peak shape and resolution. Detection may use ultraviolet absorbance, fluorescence, refractive index, or mass spectrometry, depending on the analyte and the required sensitivity.
Routine HPLC testing compares a sample result with a calibration curve prepared from known reference standards. Peak area or peak height is plotted against concentration, and the curve is used to estimate unknown amounts. Retention time supports tentative identification when compared with a standard, though mass spectrometry or another confirmatory method may be needed for definitive identification. Pre-run checks verify repeatability, resolution, and peak symmetry before sample analysis. Limits of detection and quantification describe the smallest amounts that can be reliably observed or measured. Sample preparation, filtration, and degassing help prevent column damage and inconsistent results.
For example, efavirenz and nelfinavir are two types of drugs that help decrease the HIV infection in a person's body. When the SNP from exon 26 is coupled with other SNP exons, the drugs have a lower chance of maintaining the HIV infection. Although, when the TT nucleotides in exon 26 are expressed the patient has a lower concentration of the virus but when the genotype morphs into CC or CT the infection is able to spread like normal leaving the MDR 1 gene almost defenseless. These changes in bases of exon 26 for MDR 1 show a correlation between the MDR 1 gene mutations and the ability of the antiretroviral drugs to suppress the HIV infection. Exon 26 has also been studied as to whether it is haplotype dependent or not. The presence of the SNP of exon 26 changes phenotypic functions when it is paired with the presence of mutations from exons 12 and 21. But when acting alone, it does not affect the phenotypic outcome as strongly. An example of exon 26's haplotype dependency is seen when looking at chemotherapy. Since MDR 1 removes drugs from our cells, inhibitors have been used to block MRD 1's ability to remove drugs, thus letting beneficial drugs like chemotherapy and immunosuppressants aid the body in recovery more efficiently. MDR1 has different proteins that help exile these specific drugs from cancer cells. Verapamil and cyclosporine A are common inhibitors for MDR 1.
Shrewsbury, UK: Airlife Publishing Ltd., 1992. ISBN 1-85310-212-1. Jerram, Michael F. P-51 Mustang. Yeovil, UK: Winchmore Publishing Services Ltd., 1984, ISBN 0-85429-423-6. Johnsen, Frederick A. Bell P-39/P-63 Airacobra & Kingcobra. St. Paul, Minnesota: Voyageur Press, 1998. ISBN 1-58007-010-8. Johnsen, Frederick A. North American P-51 Mustang. North Branch, Minnesota: Specialty Press Publishers and Wholesalers, 1996. ISBN 0-933424-68-X. Kaplan, Philip. Fly Navy: Naval Aviators and Carrier Aviation: A History. New York: Michael Friedman Publishing Group Incorporated, 2001. ISBN 1-58663-189-6. Kinzey, Bert. P-51 Mustang in Detail & Scale: Part 1; Prototype through P-51C. Carrollton, Texas: Detail & Scale Inc., 1996. ISBN 1-888974-02-8. Kinzey, Bert. P-51 Mustang in Detail & Scale: Part 2; P-51D thu P-82H. Carrollton, Texas: Detail & Scale Inc., 1997. ISBN 1-888974-03-6 Knaack, Marcelle Size. Encyclopedia of U.S. Air Force Aircraft and Missile Systems: Volume 1 Post-World War II Fighters 1945–1973. Washington, D.C.: Office of Air Force History, 1978. ISBN 0-912799-59-5. Lawrence, Joseph (1945). The Observer's Book Of Airplanes. London and New York: Frederick Warne & Co. Lednicer, David A. and Ian J. Gilchrist. "A Retrospective: Computational Aerodynamic Analysis Methods Applied to the P-51 Mustang." AIAA paper 91-3288, September 1991. Lednicer, David A. "Technical Note: A CFD Evaluation of Three Prominent World War II Fighter Aircraft." Aeronautical Journal, Royal Aeronautical Society, June/July 1995. Lednicer, David A.
==== Elimination ==== Ramelteon is excreted 84% in urine and 4% in feces. Less than 0.1% of drug is excreted as unchanged ramelteon. Elimination of ramelteon is essentially complete by 96 hours following a single dose. The elimination half-life of ramelteon is 1 to 2.6 hours while the half-life of M-II, the major active metabolite of ramelteon, is 2 to 5 hours. The half-lives of ramelteon and M-II are substantially longer than that of melatonin, which has a half-life in the range of 20 to 45 minutes. Levels of ramelteon and its metabolites are typically at or below the limit of detectability within 24 hours following a dose.
Sources: en.wikipedia.org
A property of DNA is its ability to re-anneal into double-stranded molecules when pH conditions are neutralized. Under neutral conditions, hydrogen bonds reform between complementary base pairs. Because the plasmid was so tightly coiled and small before the alkaline conditions were established, it can easily re-anneal. The chromosomal DNA, however, because of its lengthy strands, does not re-anneal. Once the plasmid DNA reassociates into double-stranded molecules, it dissolves into the solution. Potassium acetate reacts with the SDS detergent, magnesium ions, and calcium ions already present in the solution and forms potassium dodecyl sulfate (KDS), an insoluble white solid which precipitates out of solution. The remaining chromosomal DNA strands, denatured proteins, and added chemicals stick together and precipitate out with the KDS. The plasmid DNA, however, remains dissolved in the liquid solution. The solution is usually centrifuged to collect the insoluble precipitates into a debris pellet at the bottom of the sample tube and thereby isolate them from the supernatant.
Small clusters of cas genes are often located next to CRISPR repeat-spacer arrays. Collectively the 93 cas genes are grouped into 35 families based on sequence similarity of the encoded proteins. 11 of the 35 families form the cas core, which includes the protein families Cas1 through Cas9. A complete CRISPR-Cas locus has at least one gene belonging to the cas core. CRISPR-Cas systems fall into two classes. Class 1 systems use a complex of multiple Cas proteins to degrade foreign nucleic acids. Class 2 systems use a single large Cas protein for the same purpose. Class 1 is divided into types I, III, and IV; class 2 is divided into types II, V, and VI. The 6 system types are divided into 33 subtypes. Each type and most subtypes are characterized by a "signature gene" found almost exclusively in the category. Classification is also based on the complement of cas genes that are present. Most CRISPR-Cas systems have a Cas1 protein. The phylogeny of Cas1 proteins generally agrees with the classification system, but exceptions exist due to module shuffling. Many organisms contain multiple CRISPR-Cas systems suggesting that they are compatible and may share components. The sporadic distribution of the CRISPR-Cas subtypes suggests that the CRISPR-Cas system is subject to horizontal gene transfer during microbial evolution.
RNA sequencing (RNA-seq) RNA-seq is a high-throughput RNA sequencing technology that allows scientists to profile the entire RNA (transcriptome). Therefore, novel transcripts and gene expression level can be identified based on cDNA libraries. This method can be used for cancer diagnosis and treatment evaluation. Reverse transcription polymerase chain reaction (RT-PCR) RT-PCR is a widely used mRNA expression detection method. It enables reverse transcription of mRNA to cDNA for further identification and qualification. In early 1992, RT-PCR was applied in PSA gene expression in peripheral blood for early prostate cancer diagnosis. Digital PCR (dPCR) dPCR is a relatively accurate quantification method of measuring the initial concentration of mRNA targets. It can be applied to analyze genetic and epigenetic changes. In-situ hybridization (ISH) ISH is a tissue dependent visualization method of identifying mRNA targeted in the samples. The "tissue" can be blood sample. In chronic myeloid leukemia, ISH has been applied on peripheral-blood specimens.
Michel Gondry was working on a film adaptation in early 2011, with Steve Golin and Steve Zaillian producing. In 2014, however, Gondry told French outlet Telerama (via Jeux Actu) that he was no longer working on the project and explained: "The book is brilliant, but it's good as a literary work. Having tried to adapt it with several screenwriters, ... at the moment I don't feel up to doing it. It doesn't have the dramatic structure that would make it a good film. I received a script that disheartened me a bit, and that was it. It was a dream, but in life you can't always have what you want."
Sources: en.wikipedia.org
System suitability is a set of checks that confirm the instrument and method perform within limits before sample analysis. It typically includes resolution, tailing factor, retention time, and peak area reproducibility. If a check fails, the run is invalidated until the cause is resolved.
QC samples are usually injected at the beginning, at intervals during the run, and at the end. The exact frequency depends on the method, sample count, and regulatory requirements. Results outside acceptance limits can require rejection of the affected samples and investigation.
Method validation demonstrates that an HPLC procedure produces reliable results for its intended purpose. It provides documented evidence for accuracy, precision, specificity, and other performance characteristics. Regulators and quality systems require validation before a method is used for release or stability testing.
It is a set of checks performed before or during an HPLC run to confirm the system works as expected. Parameters may include resolution, tailing factor, theoretical plates, and retention time precision. Failure can trigger maintenance, method adjustment, or repeat analysis.